Oropharyngeal cancer: locoregional disease linked to HPV DNA levels

  • Oral Oncol

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Salivary levels of HPV DNA are associated with locoregional disease in patients with HPV-associated oropharyngeal cancer (OPC).

Why this matters

  • HPV DNA measurement might represent a noninvasive tool for predicting treatment response.

Key results

  • Recurrent, persistent locoregional disease was associated with higher median baseline normalized salivary HPV DNA compared with distant disease only (10.9 vs 0.6 copies/ng; P=.01).
  • Total tumor burden in patients with locoregional disease was associated with HPV DNA levels (P=.02).
  • HPV DNA >5 copies/ng had 87% sensitivity and 67% specificity for prediction of locoregional disease.
  • Salivary HPV DNA declined in all patients with locoregional disease response while receiving treatment.
  • Subjects who responded to locoregional cytotoxic therapy with or without radiation had a median decline in salivary HPV DNA by 3.8% per day.
  • Greater Royal Marsden Hospital prognostic score correlated with higher median plasma HPV cell-free DNA levels (P<.01 but this was not significant for normalized salivary hpv dna level>

Study design

  • 21 patients with incurable or metastatic HPV-associated OPC were included.
  • Funding: Expect Miracles Foundation; American Cancer Society; Robert A. and Renee E. Belfer Foundation.

Limitations

  • Small patient sample size.
  • Observational study.